✦ LIBER ✦

Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis

✍ Scribed by Yukio Kobayashi; Hisashi Sakamaki; Shin Fujisawa; Kiyoshi Ando; Kazuhito Yamamoto; Masaya Okada; Kenichi Ishizawa; Tadashi Nagai; Syuichi Miyawaki; Toshiko Motoji; Noriko Usui; Shinsuke Iida; Masafumi Taniwaki; Nobuhiko Uoshima; Taku Seriu; Ryuzo Ohno

Book ID: 107619308
Publisher: Carden Jennings Publishing
Year: 2011
Tongue: English
Weight: 152 KB
Volume: 93
Category: Article
ISSN: 0925-5710
DOI: 10.1007/s12185-011-0864-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Expanding Nilotinib Access in Clinical T

Expanding Nilotinib Access in Clinical Trials (ENACT) : An open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase

✍ Franck E. Nicolini; Anna Turkina; Zhi-Xiang Shen; Neil Gallagher; Saengsuree Joo 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 213 KB 👁 2 views

## Abstract ## BACKGROUND: Nilotinib is a selective, potent BCR‐ABL inhibitor. Previous studies demonstrated the efficacy and safety of nilotinib in Philadelphia chromosome‐positive chronic myeloid leukemia patients in chronic phase (CML‐CP) or accelerated phase who failed prior imatinib. ## METH